XML 78 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income (loss) $ 24,983 $ (113,678) $ (45,540)
Adjustments to reconcile net income (loss) to cash flows from operating activities:      
Depreciation and amortization 73,751 47,884 8,652
Share-based compensation expense 34,716 28,826 19,832
Loss on debt refinancing transactions 19,670    
Prepayment penalties in connection with debt refinancing transactions (6,533)    
Excess tax benefit from share-based compensation (8,867) (4,335)  
Impairment of long-lived assets 3,346 45,800  
Deferred income taxes (2,113) (14,556)  
Principal payments on long-term debt attributable to original issue discount (2,657)    
Loss on purchase of non-recourse RISPERDAL CONSTA secured 7% Notes     841
Payment or purchase of non-recourse RISPERDAL CONSTA secured 7% notes attributable to original issue discount     (6,611)
Other non-cash charges 5,698 4,342 1,861
Changes in assets and liabilities, excluding the effect of acquisitions:      
Receivables (28,239) (14,014) 2,347
Inventory, prepaid expenses and other assets (6,577) (4,879) 5,211
Accounts payable and accrued expenses 19,406 15,552 6,954
Deferred revenue (3,351) 6,068 635
Other long-term liabilities 3,318 508 (88)
Cash flows provided by (used in) operating activities 126,551 (2,482) (5,906)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Additions to property, plant and equipment (22,217) (16,988) (9,401)
Proceeds from the sale of equipment 193 35 395
Acquisition of Elan Drug Technologies, net of cash acquired   (494,774)  
Investment in Acceleron Pharmaceuticals, Inc.   (231) (501)
Promissory note issued to Civitas Therapeutics, Inc. (1,116)    
Purchases of investments (303,945) (228,229) (370,375)
Sales and maturities of investments 258,937 323,028 385,511
Cash flows (used in) provided by investing activities (68,148) (417,159) 5,629
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from the issuance of ordinary shares for share-based compensation arrangements 34,360 20,864 6,158
Excess tax benefit from share-based compensation 8,867 4,335  
Proceeds from the issuance of long-term debt 366,483 444,100  
Employee taxes paid related to net share settlement of equity awards (4,809) (3,676) (1,414)
Principal payments of long-term debt (449,944) (775)  
Payment or purchase of non-recourse RISPERDAL CONSTA secured 7% notes     (45,397)
Cash flows (used in) provided by financing activities (45,043) 464,848 (40,653)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 13,360 45,207 (40,930)
CASH AND CASH EQUIVALENTS-Beginning of period 83,601 38,394 79,324
CASH AND CASH EQUIVALENTS-End of period 96,961 83,601 38,394
SUPPLEMENTAL CASH FLOW DISCLOSURE:      
Cash paid for interest 7,656 21,658 1,684
Cash paid for taxes 5,921 10,068 60
Non-cash investing and financing activities:      
Purchased capital expenditures included in accounts payable and accrued expenses 2,450 3,416 424
Investment in Civitas Therapeutics, Inc. 1,116 1,547 1,320
Issuance of common stock used in the acquisition of Elan Drug Technologies   $ 525,074